Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
7.47
+0.07 (0.88%)
At close: Dec 27, 2024, 4:00 PM
7.53
+0.07 (0.87%)
After-hours: Dec 27, 2024, 7:03 PM EST
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $2.38M in the quarter ending September 30, 2024, a decrease of -9.81%. This brings the company's revenue in the last twelve months to $78.62M, down -33.82% year-over-year. In the year 2023, Vir Biotechnology had annual revenue of $86.18M, down -94.67%.
Revenue (ttm)
$78.62M
Revenue Growth
-33.82%
P/S Ratio
12.88
Revenue / Employee
$133,932
Employees
587
Market Cap
1.03B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Brookdale Senior Living | 2.95B |
OPKO Health | 711.41M |
ANI Pharmaceuticals | 555.46M |
Avadel Pharmaceuticals | 138.16M |
Gyre Therapeutics | 105.03M |
Bicycle Therapeutics | 36.90M |
VIR News
- 9 days ago - Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 14 days ago - Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January - Seeking Alpha
- 15 days ago - Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - Business Wire
- 4 weeks ago - Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs - Business Wire
- 4 weeks ago - Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 5 weeks ago - Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - Business Wire
- 5 weeks ago - Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - Business Wire
- 6 weeks ago - Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire